BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...in series A funding, a team of Mavupharma...
...grew out of the firm’s success with Mavupharma Inc....
...butter.Inipharm CEO Brian Farmer was CBO at Mavupharma...
BioCentury | Jan 16, 2020
Finance

Frazier taking new company creation angle with $617M fund

...a few other targets we’re looking at.” One reason for that is Frazier’s exit from Mavupharma Inc....
...to the STING pathway that could be used in cancer immunotherapy. The firm first seeded Mavupharma...
...program was de-risked over time,” Estes said (see “Mavupharma Raises $20M” ). By early 2019, Mavupharma...
BioCentury | Jul 15, 2019
Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

...The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that...
...unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma Inc.’s...
...disclose financial terms of the deal (see “Mavupharma Raises $20M Series A for STING” ). Mavupharma...
BioCentury | Dec 1, 2017
Financial News

Mavupharma raises 20M in series A round for STING modulators

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...11 ). Mavupharma Inc., Kirkland, Wash. Allison Johnson ADU-S100 Aduro Biotech Inc. Bristol-Myers Squibb Co. Cirius Therapeutics Inc. Frazier Healthcare Partners IFM Therapeutics Inc. Mavupharma Inc. Nimbus...
BioCentury | Nov 29, 2017
Financial News

Mavupharma raises $20M series A for STING

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...pathway within the tumor microenvironment or virally infected tissue. Frazier's Bob Baltera told BioCentury that Mavupharma...
Items per page:
1 - 5 of 5
BioCentury | Nov 14, 2020
Emerging Company Profile

Ex-Mavupharma execs reunite at Inipharm to build liver disease pipeline

...in series A funding, a team of Mavupharma...
...grew out of the firm’s success with Mavupharma Inc....
...butter.Inipharm CEO Brian Farmer was CBO at Mavupharma...
BioCentury | Jan 16, 2020
Finance

Frazier taking new company creation angle with $617M fund

...a few other targets we’re looking at.” One reason for that is Frazier’s exit from Mavupharma Inc....
...to the STING pathway that could be used in cancer immunotherapy. The firm first seeded Mavupharma...
...program was de-risked over time,” Estes said (see “Mavupharma Raises $20M” ). By early 2019, Mavupharma...
BioCentury | Jul 15, 2019
Company News

Via Mavupharma takeout, AbbVie gets first-in-class STING target

...The acquisition of Mavupharma gives AbbVie a first-in-class indirect STING booster close to the clinic that...
...unexploited by other companies in oncology. James Topper of Frazier Healthcare Partners, which led three-year-old Mavupharma Inc.’s...
...disclose financial terms of the deal (see “Mavupharma Raises $20M Series A for STING” ). Mavupharma...
BioCentury | Dec 1, 2017
Financial News

Mavupharma raises 20M in series A round for STING modulators

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...11 ). Mavupharma Inc., Kirkland, Wash. Allison Johnson ADU-S100 Aduro Biotech Inc. Bristol-Myers Squibb Co. Cirius Therapeutics Inc. Frazier Healthcare Partners IFM Therapeutics Inc. Mavupharma Inc. Nimbus...
BioCentury | Nov 29, 2017
Financial News

Mavupharma raises $20M series A for STING

...million in a series A round led by Frazier Healthcare Partners. Alpine BioVentures also participated. Mavupharma...
...cancer and infectious diseases. While STING's natural ligands are cyclic dinucleotides, President Michael Gallatin said Mavupharma...
...pathway within the tumor microenvironment or virally infected tissue. Frazier's Bob Baltera told BioCentury that Mavupharma...
Items per page:
1 - 5 of 5